



Date: July 28, 2022

To: All EIMPRIS team members

From: MediMergent Project Team

Memo: **Dashboard, Website, Drug Receipt**

Hello EIMPRIS Team Members,

Of no surprise, the study is moving quickly, and coordinators are asking lots of questions. Thus, processes are being refined and updated training materials are being released for your immediate review. Please read the following information very carefully and call us with any questions.

Topics covered in this Memo include:

1. **Resources Library updates**
2. **Receipt of Drug Shipment from Thermo-Fisher and the Drug Excursion Log**
3. **EIMPRIS website and Website for Patients.**

1. Resources Library on the EIMPRIS Dashboard has been updated. The Resources Library link found on the EIMPRIS SYSTEM Clinical Trials Management Dashboard has been updated. The newly reformatted page is your go to place for the supplemental resources and forms needed for the EIMPRIS Study. You will find information on the Study Drug, Lab Procedures, Regulatory Documentation, Training Materials, and many other topics. You will even find the previous EIMPRIS Memos available here. This Resources Library is intended to collect all that you need in one central location. You are encouraged to login and review this library if you have not already done so. The Resources Library will be updated as we progress through the study, so be sure to check back often.

Note: you can only access this Library through the Resources link found on the EIMPRIS SYSTEM Clinical Trials Management Dashboard.

2. Receipt of Drug Shipment from Thermo-Fisher: The Study Drug is temperature sensitive and must be stored in a controlled 2-8° C environment. **THE DRUG MUST BE REFRIGERATED IMMEDIATELY UPON ARRIVAL.** When Study Drug is delivered to your site, it should be packaged with a TempTale which records the temperature during shipment. Once you receive the shipment, you are reminded to follow the instructions to deactivate the TempTale and download the temperature log. This log can be uploaded to your regulatory portal.

If any temperature excursion is noted, the Study Drug MUST be quarantined in the refrigerator, the Drug Excursion Log (available in the Resources Library) should be completed and MediMergent should be contacted at 1-800-757-7345. You will be provided guidance on the appropriate next steps depending on your unique situation.

When Study Drug is expected, you are encouraged to alert site staff that a temperature sensitive drug will be arriving soon so they are aware that the Study Drug must be placed in the refrigerator upon receipt, the TempTale stopped, and data uploaded.

3. **EIMPRIS Websites:** There are a number of websites associated with the EIMPRIS Study. Each website has a unique and defined purpose. You are likely most familiar with the EIMPRIS SYSTEM Clinical Trials Management Dashboard (<https://app2.medimergent.com>) and the Provider training website (provider.eimpris.com)

There are also two other sites to support this study.

The first is a patient education website (participant.eimpris.com). This site can be shared with current and potential patients to inform them of the study, what to expect and how they can participate. This site is similar in format and presentation to the provider training you completed but addresses the topics most relevant to your patient. You are encouraged to review this tool and share this link with your current and potential patients.

Lastly, there is a website (eimpris.com) for the EIMPRIS program primarily used to recruit research sites and inform patients of the study. This link can be shared with other oncology practices who may want to participate in this study.

It should be noted that EIMPRIS is also listed on clinicaltrials.gov.

That is it for this edition. But stay tuned. There are some upcoming changes coming to the protocol that we will be sharing once we receive IRB approval.

As always, we want to hear from you! Let us know what we can do to help make EIMPRIS successful for you and your patients. We are all looking forward to working with you on this very important study!

Feel free to reach out to us any time at eimpris@eimpris.com or **800-757-7345**.